This adaptive dependence on higher PERK activity to combat elevated ER-stress coupled to the intrinsically low PERK levels as a result of low expression and activity of its regulator FOXO3 in these drug-resistant breast cancer cells renders them particularly vulnerable to PERK inhibition. This evidence concerns the gene FOXO3 and breast cancer.